Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 17/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | GLA | P06280 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | CASP1 | P29466 | 1/20 | 0.38 |
| ▸ | CASP7 | P55210 | 1/20 | 0.38 |
| ▸ | ATM | Q13315 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6882930 | 0.83 | ADORA2A (0.67) | ADORA2AKDM4EALDH1A1GLAGAA | |
| SCHEMBL6883012 | 0.82 | ADORA2A (0.44) | ADORA2AMEN1KMT2A | |
| SCHEMBL6879225 | 0.81 | ADORA2A (0.62) | ADORA2AKDM4EALDH1A1HPGD | |
| SCHEMBL6879136 | 0.81 | ADORA2A (0.70) | ADORA2AALDH1A1HPGDATMKMT2A | |
| SCHEMBL6883910 | 0.80 | ADORA2A (0.69) | ADORA2AHPGDATMKMT2A | |
| SCHEMBL4663631 | 0.80 | KDM4E (0.42) | ADORA2AKDM4EALDH1A1GLAGAA | |
| SCHEMBL6885011 | 0.80 | ADORA2A (0.47) | ADORA2AKDM4EALDH1A1GLAGAA | |
| SCHEMBL6882517 | 0.79 | ADORA2A (0.63) | ADORA2AHPGDATMKMT2A | |
| SCHEMBL6885567 | 0.79 | ADORA2A (0.52) | ADORA2AKDM4EALDH1A1MAPTHPGD | |
| SCHEMBL6883010 | 0.78 | ADORA2A (0.64) | ADORA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6689790-B2 | 8-AMINO-6-AMIDO-SUBSTITUTED-(1,2,4)TRIAZOLO(1,5-A)PYRIDINES; ADENOSINE RECEPTOR MODULATERS | HOFFMANN-LA ROCHE INC. | 2004-02-10 | — | — | US | disclosed |
| US-20030207911-A1 | Substituted triazolopyridine compounds | HOFFMANN-LA ROCHE INC. | 2003-11-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030207911-A1 | Substituted triazolopyridine compounds | ADORA1, CNR1, ADORA2B | ADORA2A 5/4885KDM4E 4623/4885ALDH1A1 1374/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.